Neuronetics (STIM) Competitors $3.44 +0.08 (+2.38%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$3.44 0.00 (0.00%) As of 07:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock STIM vs. EMBC, TNDM, AXGN, BBNX, SIBN, BVS, AVNS, ZIMV, KIDS, and TMCIShould you be buying Neuronetics stock or one of its competitors? The main competitors of Neuronetics include Embecta (EMBC), Tandem Diabetes Care (TNDM), AxoGen (AXGN), Beta Bionics (BBNX), SiBone (SIBN), Bioventus (BVS), AVANOS MEDICAL (AVNS), ZimVie (ZIMV), OrthoPediatrics (KIDS), and Treace Medical Concepts (TMCI). These companies are all part of the "medical equipment" industry. Neuronetics vs. Its Competitors Embecta Tandem Diabetes Care AxoGen Beta Bionics SiBone Bioventus AVANOS MEDICAL ZimVie OrthoPediatrics Treace Medical Concepts Embecta (NASDAQ:EMBC) and Neuronetics (NASDAQ:STIM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation. Do institutionals & insiders believe in EMBC or STIM? 93.8% of Embecta shares are owned by institutional investors. Comparatively, 53.6% of Neuronetics shares are owned by institutional investors. 0.4% of Embecta shares are owned by company insiders. Comparatively, 8.7% of Neuronetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is EMBC or STIM more profitable? Embecta has a net margin of 7.58% compared to Neuronetics' net margin of -43.47%. Embecta's return on equity of -23.40% beat Neuronetics' return on equity.Company Net Margins Return on Equity Return on Assets Embecta7.58% -23.40% 14.46% Neuronetics -43.47%-156.36%-35.69% Which has better earnings and valuation, EMBC or STIM? Embecta has higher revenue and earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEmbecta$1.12B0.76$78.30M$1.4310.14Neuronetics$74.89M3.04-$43.71M-$1.13-3.04 Which has more volatility & risk, EMBC or STIM? Embecta has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Neuronetics has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500. Does the media favor EMBC or STIM? In the previous week, Embecta had 10 more articles in the media than Neuronetics. MarketBeat recorded 11 mentions for Embecta and 1 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.88 beat Embecta's score of 1.30 indicating that Neuronetics is being referred to more favorably in the news media. Company Overall Sentiment Embecta Positive Neuronetics Very Positive Do analysts prefer EMBC or STIM? Embecta presently has a consensus target price of $19.00, indicating a potential upside of 31.03%. Neuronetics has a consensus target price of $7.00, indicating a potential upside of 103.49%. Given Neuronetics' stronger consensus rating and higher probable upside, analysts plainly believe Neuronetics is more favorable than Embecta.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Embecta 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.75Neuronetics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryEmbecta beats Neuronetics on 10 of the 16 factors compared between the two stocks. Get Neuronetics News Delivered to You Automatically Sign up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STIM vs. The Competition Export to ExcelMetricNeuroneticsMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$222.18M$7.06B$5.78B$9.79BDividend YieldN/A1.30%3.95%4.02%P/E Ratio-3.0426.3631.2726.59Price / Sales3.0472.95435.63155.76Price / CashN/A21.6337.7359.36Price / Book7.177.1410.966.68Net Income-$43.71M$176.42M$3.27B$265.59M7 Day Performance1.18%0.52%1.44%0.62%1 Month Performance-23.04%0.55%6.24%2.61%1 Year Performance304.75%8.35%55.09%22.34% Neuronetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STIMNeuronetics2.1202 of 5 stars$3.44+2.4%$7.00+103.5%+291.7%$222.18M$74.89M-3.04180Positive NewsEMBCEmbecta4.764 of 5 stars$14.26-0.8%$19.00+33.2%-5.9%$841.02M$1.12B9.972,100News CoveragePositive NewsAnalyst UpgradeTNDMTandem Diabetes Care4.6349 of 5 stars$12.11+1.5%$22.47+85.5%-73.4%$806.10M$940.20M-3.922,650AXGNAxoGen2.4826 of 5 stars$14.79-9.0%$26.00+75.8%+28.2%$748.16M$187.34M-147.89450News CoverageBBNXBeta Bionics1.0371 of 5 stars$17.45+2.3%$22.56+29.3%N/A$741.17M$65.12M0.00294Positive NewsSIBNSiBone4.4236 of 5 stars$16.05-2.1%$23.67+47.5%+3.5%$707.08M$167.18M-28.66350News CoverageBVSBioventus0.9073 of 5 stars$7.44-2.6%N/AN/A$631.67M$573.28M15.281,200AVNSAVANOS MEDICAL3.4191 of 5 stars$11.58-1.2%N/A-50.7%$543.37M$687.80M-1.152,227Positive NewsAnalyst RevisionZIMVZimVie0.6565 of 5 stars$18.96+0.1%$17.75-6.4%+10.6%$534.41M$449.75M-27.091,770News CoverageKIDSOrthoPediatrics4.4132 of 5 stars$20.29+0.4%$34.14+68.3%-32.2%$506.49M$204.73M-11.34200TMCITreace Medical Concepts2.2408 of 5 stars$7.47-3.0%$9.83+31.6%+18.0%$486.43M$209.36M-9.46250Positive News Related Companies and Tools Related Companies EMBC Competitors TNDM Competitors AXGN Competitors BBNX Competitors SIBN Competitors BVS Competitors AVNS Competitors ZIMV Competitors KIDS Competitors TMCI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STIM) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuronetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuronetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access